Lupin gets a clean chit from USFDA

By Research Desk
about 7 years ago

Lupin is amongst the top gainers on the BSE currently. The stock price rose over 8% intra day to Rs.1534.85 and is currently hovering at Rs.1503, up some 6%. Volumes have jumped up over two times.

The stock is reacting to the news it announced on Saturday. The company informed that it has received notification that the inspection carried out by the US FDA in March 2016 at its Goa facility is now closed and the agency has issued an Establishment Inspection Report (EIR). This closes all outstanding US FDA inspections at Lupin’s Goa facility.

The US is the biggest market for the company, accounting for 43% of the total sales of Rs13,702 crore in 2015-16.

Popular Comments

No comment posted for this article.